Trial · NCT06319846
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Any new ischemic stroke at 3-month | at 3-month | Incidence of any new ischemic stroke at 3-month |
| Primary | Type 3 or 5 bleeding events according to the BARC criteria at 3-month | at 3-month | Incidence of type 3 or 5 bleeding events according to the BARC criteria at 3-month |
| Secondary | Any new ischemic stroke within 1 year | within 1 year | Incidence of any new ischemic stroke within 1 year |
| Secondary | New clinical vascular events (ischemic stroke/ hemorrhagic stroke/ TIA/ myocardial infarction/vascular death) within 3 months and 1 year; Each new vascular event will be independently evaluated. | Within 3 months after randomization and 1 year | Incidence of new clinical vascular events (ischemic stroke/ hemorrhagic stroke/ TIA/ myocardial infarction/vascular death) within 3 months and 1 year; Each new vascular event will be independently evaluated. |
| Secondary | Disabling stroke (Modified Rankin Scale score, mRS>1) at 3 months and 1 year | at 3 months and 1 year | Proportion of patients with disabling stroke (Modified Rankin Scale score, mRS\>1) at 3 months and 1 year. Scores on the modified Rankin scale range from 0 (no neurologic deficit) to 6 (death). |
| Secondary | Incidence and severity of recurrent stroke and TIA | Within 3 months after randomization and 1 year | Incidence and severity of recurrent stroke and TIA during follow-up to 3 months and 1-year (Severity is measured using a six-level ordered categorical scale that incorporates the mRS: fatal stroke/severe non-fatal stroke \[mRS 4 or 5\]/moderate stroke \[mRS 2 or 3\]/mild stroke \[mRS 0 or 1\]/TIA/no stroke-TIA) |
| Secondary | Neurological impairment at 3 months (NIHSS increased≥4 from baseline ). | at 3 months | Proportion of patients with neurological impairment at 3 months ( National Institutes of Health Stroke Scale \[NIHSS\] score increased≥4 from baseline). |
| Other | Type 3 or 5 bleeding events (BARC definition) at 1 year | at 1 year | Proportion of patients with type 3 or 5 bleeding events (BARC definition) at 1 year. |
| Other | Type 2, 3 or 5 bleeding events according to the BARC criteria at 3-month and 1-year. | at 3-month and 1-year | Proportion of patients with type 2, 3 or 5 bleeding events according to the BARC criteria at 3-month and 1-year. |
| Other | All bleeding events (type 1-5 bleeding events according to the BARC criteria) | at 3-month and 1-year | All bleeding events (type 1-5 bleeding events according to the BARC criteria) at 3-month and 1-year; Each bleeding event will be independently evaluated |
| Other | Total mortality at 3-month and 1-year | at 3-month and 1-year | Proportion of patients with total mortality at 3-month and 1-year |
| Other | Adverse events/Severe adverse events reported by investigators at 3-month and 1-year | at 3-month and 1-year |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06319846/registered